Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Gross Margin of 77.05% for Q1 2026, down 965.0% year-over-year from 8.91% in Q1 2025, and down 1.53% quarter-over-quarter from 78.25% in Q4 2025.
Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Gross Margin for 9 consecutive years, with 77.05% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 965.0% year-over-year to 77.05%; the TTM figure through Mar 2026 stood at 81.01% (up 328.0% YoY), while the FY2025 annual figure was 83.29%, up 23.0% from the prior year.
- Gross Margin eased to 77.05% in Q1 2026 per AKBA's latest filing, from 78.25% in the prior quarter.
- Across five years, Gross Margin topped out at 86.7% in Q1 2025 and bottomed at 30301.32% in Q1 2022.
- Historically, Gross Margin has averaged 1715.19% across 5 years, with a median of 75.58% in 2024.
- Annual changes were most pronounced in 2022 — Gross Margin tumbled 3035238 bps — and 2023, when it jumped 3037337 bps.
- Akebia Therapeutics' Gross Margin stood at 57.69% in 2022, then surged by 44 bps to 82.82% in 2023, then decreased by 9 bps to 75.58% in 2024, then grew by 4 bps to 78.25% in 2025, then slipped by 2 bps to 77.05% in 2026.
- Business Quant data shows AKBA's Gross Margin at 77.05% in Q1 2026, 78.25% in Q4 2025, and 84.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Akebia Therapeutics | 245.42 Mn | 89.87 Mn | 38.70 Mn | 78.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.78% |
| Mar 31, 2026 | 77.05% |
| Dec 31, 2025 | 78.25% |
| Sep 30, 2025 | 84.03% |
| Jun 30, 2025 | 84.12% |
| Mar 31, 2025 | 86.70% |
| Dec 31, 2024 | 75.58% |
| Sep 30, 2024 | 86.24% |
| Jun 30, 2024 | 60.94% |
| Mar 31, 2024 | 64.41% |
| Dec 31, 2023 | 82.82% |
| Sep 30, 2023 | 57.17% |
| Jun 30, 2023 | 69.34% |
| Mar 31, 2023 | 72.06% |
| Dec 31, 2022 | 57.69% |
| Sep 30, 2022 | 21.42% |
| Jun 30, 2022 | 85.28% |
| Mar 31, 2022 | -30,301.32% |
| Dec 31, 2021 | 107.62% |
| Sep 30, 2021 | 85.78% |